Uses of DHEA in aging and other disease states

被引:59
作者
Johnson, MD [1 ]
Bebb, RA [1 ]
Sirrs, SM [1 ]
机构
[1] Univ British Columbia, Div Endocrinol, Vancouver, BC V5Z 1C6, Canada
关键词
DHEA; AIDS; cancer; aging; cardiovascular disease;
D O I
10.1016/S0047-6374(01)00369-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Dehydro-3-epiandrosterone is a steroid hormone synthesized in large quantities by the adrenal gland whose physiologic role remains unclear. The effects of DHEA could be estrogenic or androgenic, depending on the hormonal milieu. Low levels of DHEA are associated with aging, cardiovascular disease in men, and an increased risk of premenopausal breast and ovarian cancer. High levels of DHEA might increase the risk of postmenopausal breast cancer. Therapeutically DHEA might be useful for improving psychological well-being in the elderly, reducing disease activity in people with mild to moderate systemic lupus erythernatosus and myotonic dystrophy, improving mood in those clinically depressed, and improving various parameters in women with adrenal insufficiency. Although many other claims have been made for DHEA in diverse conditions, such as aging, dementia, and AIDS, no well-designed clinical trials have clearly substantiated the utility and safety of long-term DHEA supplementation. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 41
页数:13
相关论文
共 63 条
[1]   Dehydroepiandrosterone replacement in women with adrenal insufficiency [J].
Arlt, W ;
Callies, F ;
van Vlijmen, JC ;
Koehler, I ;
Reincke, M ;
Bidlingmaier, M ;
Huebler, D ;
Oettel, M ;
Ernst, M ;
Schulte, HM ;
Allolio, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (14) :1013-1020
[2]   The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life [J].
Barnhart, KT ;
Freeman, E ;
Grisso, JA ;
Rader, DJ ;
Sammel, M ;
Kapoor, S ;
Nestler, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :3896-3902
[3]   DEHYDROEPIANDROSTERONE-SULFATE DOES NOT PREDICT CARDIOVASCULAR DEATH IN POSTMENOPAUSAL WOMEN - THE RANCHO-BERNARDO STUDY [J].
BARRETTCONNOR, E ;
GOODMANGRUEN, D .
CIRCULATION, 1995, 91 (06) :1757-1760
[4]   A PROSPECTIVE-STUDY OF DEHYDROEPIANDROSTERONE SULFATE, MORTALITY, AND CARDIOVASCULAR-DISEASE [J].
BARRETTCONNOR, E ;
KHAW, KT ;
YEN, SSC .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (24) :1519-1524
[6]   Dehydroepiandrosterone (DHEA): A fountain of youth? [J].
Baulieu, EE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) :3147-3151
[7]  
BELANGER A, 1994, J CLIN ENDOCR METAB, V79, P1086
[8]  
Bergeron R, 1996, J NEUROSCI, V16, P1193
[9]   REDUCED ADRENAL ANDROGENS IN PATIENTS WITH MYOTONIC-DYSTROPHY [J].
CARTER, JN ;
STEINBECK, KS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (03) :611-614
[10]   Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial [J].
Casson, PR ;
Santoro, N ;
Elkind-Hirsch, K ;
Carson, SA ;
Hornsby, PJ ;
Abraham, G ;
Buster, JE .
FERTILITY AND STERILITY, 1998, 70 (01) :107-110